HomeCompareCYAD vs MCD

CYAD vs MCD: Dividend Comparison 2026

CYAD yields 425.53% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYAD wins by $18058.52M in total portfolio value
10 years
CYAD
CYAD
● Live price
425.53%
Share price
$0.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18058.60M
Annual income
$12,349,610,253.13
Full CYAD calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — CYAD vs MCD

📍 CYAD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYADMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYAD + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYAD pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYAD
Annual income on $10K today (after 15% tax)
$36,170.21/yr
After 10yr DRIP, annual income (after tax)
$10,497,168,715.16/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, CYAD beats the other by $10,497,146,421.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYAD + MCD for your $10,000?

CYAD: 50%MCD: 50%
100% MCD50/50100% CYAD
Portfolio after 10yr
$9029.34M
Annual income
$6,174,818,240.41/yr
Blended yield
68.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

CYAD
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Altman Z
-41.9
Piotroski
2/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYAD buys
0
MCD buys
0
No recent congressional trades found for CYAD or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYADMCD
Forward yield425.53%2.35%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$18058.60M$78.5K
Annual income after 10y$12,349,610,253.13$26,227.70
Total dividends collected$17541.95M$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: CYAD vs MCD ($10,000, DRIP)

YearCYAD PortfolioCYAD Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$53,253$42,553.19$10,815$334.85+$42.4KCYAD
2$268,765$211,784.42$11,826$491.71+$256.9KCYAD
3$1,286,515$998,936.38$13,123$730.06+$1.27MCYAD
4$5,845,421$4,468,849.76$14,853$1,100.07+$5.83MCYAD
5$25,230,957$18,976,356.52$17,257$1,690.61+$25.21MCYAD
6$103,547,438$76,550,313.71$20,752$2,667.01+$103.53MCYAD
7$404,404,397$293,608,638.27$26,103$4,354.83+$404.38MCYAD
8$1,504,383,912$1,071,671,207.21$34,794$7,437.78+$1504.35MCYAD
9$5,335,499,864$3,725,809,078.26$49,926$13,461.60+$5335.45MCYAD
10$18,058,595,107$12,349,610,253.13$78,550$26,227.70+$18058.52MCYAD

CYAD vs MCD: Complete Analysis 2026

CYADStock

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Full CYAD Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this CYAD vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYAD vs SCHDCYAD vs JEPICYAD vs OCYAD vs KOCYAD vs MAINCYAD vs YUMCYAD vs QSRCYAD vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.